Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 138

Targeting DIPG through pharmacological activation of mitochondrial biogenesis: as in ...

Diffuse intrinsic pontine gliomas (DIPG) are infiltrative, highly aggressive pediatric brainstem tumors with limited therapeutic options. Despite international efforts to improve outcome, DIPG show poor response to conventional radiation and chemotherapeutic strategies. Only within the last decade have studies really begun to decipher the molecular mechanisms behind DIPG tumorigenesis, with ...

Sequential phase I studies of nivolumab monotherapy and nivolumab in ...

Developing effective treatments for pediatric CNS tumors arguably represents the major remaining unmet need in pediatric oncology.  We propose a phase I study of nivolumab and then another phase I study of the combination of ipilimumab and nivolumab in children with recurrent/refractory brain tumors. Ipilimumab ...

Therapeutic reversal of pre-natal pontine ID1 signaling in DIPG

Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain tumor wand few children with this diagnosis survive up to two years. Even with the advent of precision-based medicine, experimental therapies have yet to show benefit beyond standard radiation, highlighting the dire need to identify and investigate novel genetic therapeutic ...

PRE-CLINICAL DEVELOPMENT OF NOVEL DIPG RADIOSENSITIZERS

Hypothesis: Diffuse intrinsic pontine glioma (DIPG) is a devastating disease with an almost universally fatal prognosis. Despite many clinical trials testing numerous chemotherapies and targeted systemic agents, both concurrent with RT and in the adjuvant setting, these therapies have not changed OS. We and others believe that 3 major issues contribute ...

Development of subgroup-specific models of paediatric DIPG

 Brain tumors are the largest group of solid tumors and the leading cause of cancer-related deaths in childhood1. The most devastating of these is DIPG, an incurable brainstem tumor with a median survival of less than one year2,3. DIPGs show poor response to conventional radiation and chemotherapeutic strategies used ...